Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience

J Neurooncol. 2009 Jan;91(2):227-32. doi: 10.1007/s11060-008-9703-5. Epub 2008 Sep 24.

Abstract

Background: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH).

Methods: Between 1977 and 2002, 27 patients with intracranial germinoma were treated with radiation therapy (RT). In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up.

Results: Five patients (18%) developed a ST of which 4 (15%) were malignant. One developed a benign falcine meningioma. The cumulative incidence of ST was 9% at 11 years (95% CI, 0-22%).

Conclusions: The relative contributions of RT and patient susceptibility to a ST cannot be determined but suggests the need for long-term surveillance, including testicular self-exams in male germinoma survivors. Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower risk of treatment-induced ST.

MeSH terms

  • Adolescent
  • Adult
  • Brain Neoplasms / radiotherapy
  • Child
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Germinoma / radiotherapy
  • Humans
  • Incidence
  • Male
  • Neoplasms, Radiation-Induced / epidemiology*
  • Neoplasms, Radiation-Induced / etiology*
  • Neoplasms, Second Primary / epidemiology*
  • Neoplasms, Second Primary / etiology*
  • Radiotherapy / adverse effects*
  • Retrospective Studies
  • Risk Assessment
  • Risk*
  • Time Factors
  • Treatment Outcome